Canaccord Genuity analyst William Plovanic maintained a Buy rating on Shockwave Medical (NASDAQ:SWAV) on Monday, setting a price target of $202, which is approximately 49.85% above the present share price of $134.8.
Plovanic expects Shockwave Medical to post earnings per share (EPS) of -$0.46 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Shockwave Medical, with an average price target of $174.75.
The analysts price targets range from a high of $202 to a low of $152.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $22.72 million and a net profit of -$15.87 million. The company's market cap is $4.71 billion.
According to TipRanks.com, Canaccord Genuity analyst William Plovanic is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.6% and a 49.83% success rate.
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins (NASDAQ:HWKN), John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.